Jinan High-tech Development Co., Ltd. Class A

Jinan High-tech Development Co., Ltd. Class A

SSSE:600807
2.32
CNY
-0.06
(-2.52%)
-0.29EPS
2.37BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.3
1.66
1.71
2.48
2.44
1.68
1.98
1.26
1.75
1.87
0.83
0.43
0.41
0.47
Basic EPS, GAAP
-0.08
0.14
0.16
0.15
-0.56
0.04
0.07
-0.95
0.02
0.02
-0.11
-0.93
-0.24
-0.25
Free Cash Flow per Basic Share
-0.62
-0.19
-0.28
-1.65
-2.27
1.59
0.55
0.66
-1.35
-0.9
-0.41
0.01
0.04
- -
Dividend per Share
0.08
0.32
0.21
0.33
0.41
0.05
0.18
0.1
0.07
0.16
0.04
0.03
0.01
0.01
Book Value per Share
0.49
0.83
1.98
2.17
1.41
1.39
1.47
0.55
0.5
0.4
0.24
0.09
0.34
0.3
Tangible Book Value per Share
-0.04
0.55
1.77
1.71
0.92
1.04
1.43
0.35
0.31
0.04
- -
-0.07
0.28
0.24
Basic Weighted Avg Shares
647
511
720
902
866
897
902
868
734
919
865
866
868
844
Sales/Revenue/Turnover
840
846
1,228
2,240
2,115
1,504
1,784
1,092
1,285
1,717
716
372
352
401
Operating Margin (%)
0.98
16.9
20.9
21.25
22.06
5.09
24.35
14.39
26.41
26.95
-0.76
-14.52
-14.68
-17.05
Depreciation Expense
12
20
16
69
131
228
139
78
65
148
23
17
14
- -
Net Income, GAAP
-55
72
115
135
-485
36
63
-825
15
18
-95
-806
-208
-207
Effective Tax Rate (%)
- -
12.9
17.24
13.29
- -
47.21
61.69
- -
20.88
61.82
- -
- -
- -
- -
Profit Margin (%)
-6.52
8.45
9.38
6.04
-22.93
2.39
3.54
-75.57
1.14
1.07
-13.28
-216.51
-59.22
-51.65
Working Capital
719
775
1,079
1,804
885
406
-262
-302
-702
341
79
535
810
801
LT Debt
910
628
410
1,848
1,708
515
334
40
164
309
26
27
20
16
Total Equity
329
721
1,755
1,927
1,258
1,241
1,313
649
641
834
576
378
546
500
Return on Invested Capital (%)
- -
4.12
4.62
2.13
- -
-16.18
3.66
- -
10.55
6.92
- -
- -
- -
- -
Return on Capital (%)
- -
6.2
6.74
7.72
- -
16.48
5.15
- -
3.9
0.36
- -
- -
- -
- -
Return on Common Equity (%)
-15.69
18.02
10.09
7.5
-30.7
2.9
5
-92.47
3.16
4.64
-33.71
-551.05
-109.76
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
66
54
47
LT Borrowings
18
17
15
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
885
885
885
Market Capitalization
2,849
2,070
2,371

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,821
1,829
1,822
Cash, Cash Equivalents & STI
812
795
827
Accounts Receivable, Net
236
249
260
Inventories
598
607
542
Total Current Liabilities
1,011
1,033
1,021
Payables & Accruals
- -
- -
- -
ST Debt
66
54
47
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.29%
1.63%
44.59%
Free Cash Flow
41.33%
-6.54%
413.71%
Net Income, GAAP
-190.03%
-4.24%
-74.15%
Sales/Revenue/Turnover
-3.27%
-12.1%
-5.49%
Total Cash Common Dividend
20.79%
-2.6%
-60.8%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
56
152
62
103
372
2025
88
71
- -
130
352
2026
53
84
135
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.01
-0.02
-0.88
-0.93
2025
-0.03
-0.02
- -
-0.15
-0.24
2026
-0.03
-0.04
-0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
- -
0.03
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

CEO
Yongbo Yang
Full Time Employees
551
Sector
Finance
Industry
Real estate development
Address
Building A4-4, Hanyu Financial and Business Center Jinan SD China 250101
IPO Date
Jan 3, 1994
Business
Jinan High-tech Development Co., Ltd. (600807.SS) is a China-based diversified company principally engaged in the in vitro diagnostics business, alongside real estate development, property services, trading, and other operations; it operates three main segments including the Real Estate and Property Services segment focused on real estate development, sales, property management, and leasing; the In Vitro Diagnostics segment encompassing research, development, production, and sales of molecular diagnostic reagents, molecular diagnostic automated testing equipment, biological sample library management software, biological sample intelligent storage cabinets, biological sample intelligent management terminals, and medical testing services primarily for infectious disease prevention and control, pathogenic microorganism detection, and food safety testing; and the Other Business segment covering trading activities such as steel rebar procurement and sales. The company also maintains involvement in industrial park investment, development, and operation; precious and non-ferrous metals exploration, mining, and processing including copper, lead, zinc, gold, and silver; property consulting and leasing; greening, landscaping, municipal engineering, garden design, and maintenance; agricultural machinery leasing; construction project quality inspection; equity investment; business management consulting; hotel management; and labor services, primarily targeting markets in China with operations centered in Shandong Province. Founded in 1993 and headquartered at 3F, Section A, Jinan International Convention & Exhibition Center, No. 1 Xinyu South Road, High-Tech Development Zone, Jinan, Shandong, China, the company employs approximately 565 people and lists on the Shanghai Stock Exchange. Recent developments include the wholly-owned subsidiary Shandong Ruifuxiang Trading Co., Ltd. signing a 2025-2026 Annual Steel Rebar Centralized Procurement Global Strategy Agreement with Jinan High-tech Development Group Co., Ltd. in August 2025; completion of a passive shareholding reduction by controlling shareholder affiliate Jinan Dongxin Construction and Development Co., Ltd. involving 1.21% of shares in July 2025; registration and establishment of Jinan Guangyao Industrial Investment and Development Partnership with approximately RMB 700 million investment; termination of a pastoral complex project; release of the 2025 semi-annual and third-quarter reports amid ongoing net losses; and continued emphasis on in vitro diagnostics products like molecular reagents and equipment alongside steel bars trading.